Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings
Abdulraheem Yacoub(The University of Kansas Cancer Center), Robert S. Hoffman(New York City Department of Health and Mental Hygiene), Vittorio Rosti(Istituti di Ricovero e Cura a Carattere Scientifico), Murat O. Arcasoy(Duke University), Lonette Sandy(Icahn School of Medicine at Mount Sinai), Adam J. Mead(National Institute for Health and Care Research), Damiano Rondelli(University of Illinois Chicago), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Craig M. Kessler(Georgetown University), Heidi Kosiorek(Mayo Clinic in Florida), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Richard T. Silver(Cornell University), Josef T. Prchal(Huntsman Cancer Institute), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), Maria R. Baer(University of Maryland, Baltimore), Rona Singer Weinberg(University of North Carolina at Chapel Hill), Casey L. O’Connell(University of Southern California), Valerio De Stefano(Agostino Gemelli University Polyclinic), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Marina Kremyanskaya(Tisch Cancer Institute), Tiziano Barbui(University of Bergamo), John Mascarenhas(Tisch Hospital), Mary Frances McMullin(Queen's University Belfast), Olivia Siwoski(The University of Kansas Cancer Center), Raajit K. Rampal(Memorial Sloan Kettering Cancer Center), Ellen K. Ritchie(Cornell University), Amylou C. Dueck(Mayo Clinic in Arizona), Elizabeth O. Hexner(University of Pennsylvania), Joanne Ewing(Heart of England NHS Foundation Trust), Jean‐Jacques Kiladjian(Délégation Paris 5), Elliott F. Winton(Emory University), Joseph Vadakara(Geisinger Medical Center)
Cited by 5
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
|JAMA|2017|2.3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k